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Protocol
AbstrACt
Introduction South Australia (SA) has the highest 
notification rate of invasive meningococcal disease in 
Australia with the majority of cases due to serogroup 
B. Neisseria meningitidis is carried in the pharynx, with 
adolescents having the highest rates of carriage. A vaccine 
designed to offer protection against serogroup B (4CMenB) 
is licensed in Australia. The SA MenB vaccine carriage 
study aims to assess the impact of 4CMenB on carriage of 
N. meningitidis in adolescents.
Methods and analysis This is a parallel cluster randomised 
controlled trial enrolling year 10, 11 and 12 school 
students (approximately 16–18 years of age) throughout 
SA, in metropolitan and rural/remote areas. Schools 
are randomised to intervention (4CMenB vaccination 
at baseline) or control (4CMenB vaccination at study 
completion) with randomisation stratified by school size 
and socioeconomic status, as measured by the Index 
of Community Socio-Educational Advantage (Australian 
Curriculum). Oropharyngeal swabs will be taken from all 
students at visit 1, and 12 months later from year 11 and 
12 students. Students unvaccinated in 2017 will receive 
vaccine at the 12-month follow-up. Carriage prevalence of 
N. meningitidis will be determined by PCR at baseline and 12 
months following 4CMenB vaccination and compared with 
carriage prevalence at 12 months in unvaccinated students. 
A questionnaire will be completed at baseline and 12 
months to assess risk factors associated with carriage. The 
primary outcome of carriage prevalence of disease causing 
N. meningitidis at 12 months will be compared between 
groups using logistic regression, with generalised estimating 
equations used to account for clustering at the school level. 
The difference in carriage prevalence between groups will be 
expressed as an OR with 95% CI.
Ethics and dissemination The study was approved 
by the Women’s and Children’s Health Network Human 
Research Ethics Committee (WCHN HREC). The protocol, 
informed consent forms, recruitment materials, social 
media and all participant materials have been reviewed 
and approved by the WCHN HREC and updated on  
ClinicalTrials. gov. Results will be published in international 
peer-reviewed journals and presented at national and 
international conferences. The study findings will be 
provided in public forums and to study participants and 
participating schools.
trial registration number ACTRN12617000079347. 
NCT03089086; Pre-results.
IntroduCtIon
Neisseria meningitidis infection is an important 
cause of morbidity (~500 000–1 200 000 
cases/year) and mortality (50 000–135 000 
deaths/year) worldwide.1 2 Clinically, the 
most important serogroups are A, B, C, W, 
X and Y. The global serogroup distribution 
is dynamic over time and there are regional 
variations in disease epidemiology.3 
Carriage of N. meningitidis
Exposure to N. meningitidis is common in the 
general population, leading to asymptomatic 
pharyngeal carriage that may be transient, 
temporary or long term. Age influences 
carriage, with a rapid rise from 15 years of age 
to a peak in carriage at around 19 years, likely 
strengths and limitations of this study
 ► A parallel cluster randomised controlled trial will 
allow a causal determination of the impact of me-
ningococcal B vaccine on oropharyngeal carriage of 
Neisseria meningitidis.
 ► The primary outcome is an objective measure, lab-
oratory confirmed PCR positivity, which is measured 
by one centralised laboratory.
 ► This clinical trial will be the largest interventional 
population study of its kind.
 ► Attrition of participants over the 12-month follow-up 
may compromise group comparisons.
 ► Control and intervention students are independent 
but limited school mixing between schools may oc-
cur reducing the estimation of impact of 4CMenB 
on carriage.
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due to increases in the number and closeness of social 
contacts.4 5 Other factors that influence carriage are 
male gender, concomitant or predisposing respiratory 
infections, active and passive smoking, and low socioeco-
nomic status.6 Disease is a rare outcome of infection and 
the relationship between carriage and disease incidence 
is not fully understood.4 7 Given that carriage and trans-
mission rates are significantly higher in adolescents than 
other members of the population and very low in infants, 
a reduction of carriage in adolescents has the potential to 
provide indirect protection to unvaccinated individuals, 
including infants.8
Epidemiology in Australia and south Australia
As in many countries, the incidence of invasive meningo-
coccal disease (IMD) in Australia is highest in children 
under 1 year of age (3.7/100 000), followed by adoles-
cents between the ages of 15 and 19 years (2.6/100 000).9 
In 2016, 262 cases of IMD were notified nationally 
(1.1/100 000), with 28 notifications in South Australia 
(SA) including one death.10 SA has a population of 
1.7 million and has the highest notification rate of IMD 
in Australia (1.65/100 000), with serogroup B predomi-
nating (n=23/28, 82%; 2016).10 The most common sero-
group causing IMD nationally between 1999 and 2015 
was serogroup B. In 2016, serogroup W notifications 
exceeded serogroup B notifications nationally (110 vs 93 
cases, respectively).10
Meningococcal vaccines and herd protection
Since the early 2000s, countries that offer universal vacci-
nation against meningococcal serogroup C (MenC) have 
seen a dramatic decrease in the incidence of serogroup 
C disease.11–13 Aligned to this, where adolescents have 
been targeted for vaccination, carriage of serogroup C 
in adolescents has reduced, resulting in indirect protec-
tion through reduced transmission and herd protection, 
with disease rates reduced across all age groups as a 
consequence.12 13 The ability of a meningococcal vaccine 
to impact colonisation and transmission of meningo-
cocci and, in turn, provide indirect effects through herd 
protection has important implications for evaluating the 
population impact and risk/benefit of the vaccine and 
for determining vaccine policy. As a result, there is high 
interest in assessing meningococcal B vaccines in relation 
to their impact on carriage, ideally in a large postlicen-
sure population study.14
In Australia, 4CMenB is registered for use in persons ≥2 
months of age for the prevention of invasive disease caused 
by serogroup B meningococci and is recommended by 
the Australian Technical Advisory Group on Immunisa-
tion for children <2 years of age and adolescents 15–19 
years of age.15 However, 4CMenB is only available through 
purchase on the private market in Australia as it has not 
been included on the National Immunisation Program. 
The Pharmaceutical Benefits Advisory Committee, 
Commonwealth Government, which reviewed the cost-ef-
fectiveness of a meningococcal B vaccine programme in 
2013, identified lack of data on effectiveness in a popula-
tion programme (prior to implementation of the infant 
programme in the UK) and herd protection to inform 
cost-effectiveness estimates.16
In contrast to serogroups A, C, W and Y, the poor immu-
nogenicity of the meningococcal serogroup B polysaccha-
ride capsule, coupled with the marked genetic variability 
of the immunodominant serogroup B surface proteins, 
has prevented the development of a universal serogroup 
B vaccine. As the meningococcal B vaccines have been 
developed with novel technologies, their ability to induce 
herd protection is unknown.14 In Australia, based on the 
Meningococcal Antigen Typing System data, approxi-
mately 76% of 373 MenB isolates from invasive disease 
collected from 2007 to 2011 were predicted to be covered 
by this vaccine with the predicted coverage for SA at that 
time being 90%. A recent longitudinal study covering the 
past 15-year (2000–2014) history of meningococcal disease 
in Western Australia, a neighbouring state, indicates that 
although there was fluctuation over time in MenB vaccine 
coverage, the overall 15-year average remained high (60% 
with an annual range of 40% to 82%).17
Vaccine effectiveness in an infant 4CMenB popula-
tion programme in the UK has been reported as 82.9% 
(95% CI 24.1 to 95.2).18
In the UK, a randomised, multicentre controlled study 
was conducted to examine carriage in university students 
18–24  years  old pre-vaccination and at serial follow-up 
points post-vaccination with 4CMenB.19 From 3 months 
after dose 2, 4CMenB vaccination resulted in significantly 
lower carriage of any meningococcal genogroup (18.2% 
(95% CI 3.4 to 30.8) carriage reduction) and 26.6% 
(95% CI 10.5 to 39.9) reduction in genogroups BCWY. 
A significant carriage reduction for disease-associated 
sequence types of capsular B meningococci compared 
with controls was not observed (12.6% (95% CI 
−15.9 to –34.1). This non-significant finding may in 
part be attributable to low acquisition of meningococcal 
strains, a low level of expression of vaccine antigens in 
carriage isolates, a slower-than-expected enrolment and 
limited vaccination prior to or during the period of 
maximal carriage acquisition.19
The SA MenB vaccine carriage study ‘B Part of It’ aims 
to assess the impact of 4CMenB on carriage of disease 
causing N. meningitidis by comparing carriage preva-
lence at 12 months post-implementation of a MenB 
vaccine programme in schools, with participating schools 
randomised to intervention or control.
MEthods And AnAlysIs
study design
This parallel cluster randomised controlled trial will 
measure the impact of 4CMenB on carriage prevalence 
in adolescents in SA. All 260 schools in metropolitan and 
rural/remote SA are invited to participate with immu-
nisation provided through the school immunisation 
programme, managed by the Immunisation Branch, SA 
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Health, in SA. For the purposes of the study, a school is 
defined as an educational institution at which students 
in years 10, 11 and 12 physically attend school during 
the week. Each school year level in SA has a cohort of 
19 000–20 000 students aged approximately 16–18 years, 
with year 12 being the final year of school.
As carriage of the meningococcus is temporary and 
fluctuates over time and the adolescent years, a control 
group is essential to assess a causal relationship between 
the intervention, MenB vaccination and any change 
in carriage prevalence during this study. Two doses of 
4CMenB will be given with a 2-month interval to all 
students attending school in years 10, 11 and 12. Indi-
viduals eligible to be enrolled into this study are South 
Australian secondary school students in years 10, 11 and 
12 in 2017, who provide informed consent, are avail-
able at school for at least the first oropharyngeal swab 
and willing to comply with study procedures. Students 
are ineligible if they have previously received any doses 
of Bexsero (4CMenB) or had an anaphylactic reaction 
to any component of the vaccine or are known to be 
pregnant.
All students will undergo baseline oropharyngeal 
swab sampling, with schools randomised for students to 
receive either 4CMenB in 2017 (group A) or 4CMenB 
in 2018 (group B) (figure 1). The latter will receive 
4CMenB at the 12-month follow-up swab visit. As 
follow-up swabs will only be available for year 10 and 
11 students, the primary outcome is PCR positivity in 
year 10 and 11 students enrolled in the study. Year 12 
students will undergo baseline posterior oropharyn-
geal swabs only. Year 12 students in group B will be 
offered 4CMenB vaccine in 2018 at designated immu-
nisation clinics as the majority will have completed 
school in 2017. The advantages of conducting a study 
in school rather than university students include the 
opportunity to vaccinate prior to rapid carriage acqui-
sition and the relatively closed accessible environment 
with an existing vaccination programme infrastructure. 
Year 12 students are included as they are likely to have 
the highest carriage rates and mixing of unimmunised 
year 12 students with immunised year 10 and 11 
students could potentially reduce any vaccine impact 
on carriage.
Primary objective
 ► Estimate the difference in overall carriage prevalence 
of disease causing genogroups of N. meningitidis (A, B, 
C, W, X, Y) following the 12-month pharyngeal swab 
in year 10 and 11 students who received two doses of 
Bexsero, compared with unvaccinated students.
secondary objectives
 ► Estimate the difference in carriage prevalence of each 
disease causing genogroup of N. meningitidis (A, B, 
C, W, X, Y) following the 12-month pharyngeal swab 
in year 10 and 11 students who received two doses of 
Bexsero, compared with unvaccinated students.
 ► Estimate the difference in carriage prevalence of all 
genogroups of N. meningitidis following the 12-month 
pharyngeal swab in year 10 and 11 students who 
received two doses of Bexsero, compared with unvac-
cinated students.
 ► Estimate the difference in acquisition (negative at 
baseline, positive at 12-month follow-up) of carriage 
of disease-causing genogroups of N. meningitidis (A, B, 
C, W, X, Y) over a 12-month period in students who 
received two doses of Bexsero , compared with unvac-
cinated students.
 ► Estimate the difference in acquisition (negative at 
baseline, positive at 12-month follow-up) of carriage 
of all genogroups of N. meningitidis over a 12-month 
period in students who received two doses of Bexsero, 
compared with unvaccinated students.
 ► Identify characteristics associated with carriage prev-
alence of all genogroups of N. meningitidis in South 
Australian school students at baseline and 12 months.
 ► Identify characteristics associated with carriage preva-
lence of disease causing genogroups of N. meningitidis 
(A, B, C, W, X, Y) in South Australian school students 
at baseline and 12 months.
randomisation
Randomisation will take place at the school level and 
will be stratified by school size (<60, 60 to 119, and ≥120 
students per year level) and school socioeconomic status, 
as measured by the Index of Community Socio-Ed-
ucational Advantage (ICSEA); (ICSEA <970, 970 to 
1020, >1020).20 All schools agreeing to participate will be 
randomised to intervention (4CMenB vaccine) in 2017 
or control (vaccination at the follow-up visit in 2018) 
(figure 1). The randomisation schedule will be generated 
by an independent statistician not otherwise involved in 
the study using Stata V.14. Schools and students will be 
unaware of their allocation to intervention or control 
until the day of the study immunisation provider visit. 
Laboratory personnel are blinded to assignment of inter-
vention or control for the duration of the study.
study processes
Immunisation providers will be trained in all aspects of 
the study processes, including collection of a posterior 
oropharyngeal swab, using a standardised technique. 
A flocculated swab will be wiped across the posterior 
oropharynx from one tonsillar area to the other and the 
swab placed immediately in STGG (skim milk, tryptone, 
glucose, glycerine; Thermo-Fisher Scientific Australia) 
transport medium.21 Swab vials will be labelled and 
placed in a portable cooler and delivered to the nearest 
SA Pathology collection centre.
School immunisation providers and the study team will 
approach all schools in SA to confirm their involvement 
in the study. Consent forms and information sheets will 
be sent home to parents and both parental consent and 
student assent will be obtained. Consent forms will be 
collected from the schools by the immunisation nurses, 
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checked for completeness and data entered into the desig-
nated ‘B Part of It’ study web-based database established 
by Adelaide Health Technology Assessment (AHTA), The 
University of Adelaide.
Immunisation providers will explain the process of swab 
collection and immunisation to each student prior to any 
procedures being performed. All students will have an 
oropharyngeal swab taken and complete the risk factor 
questionnaire from 1 April to 30 June 2017. All group A 
students will be administered the first dose of 4CMenB 
(figure 1).
Participants will be asked to complete a one page 
de-identified questionnaire to collect information on 
characteristics that may be relevant to carriage of N. 
meningitidis (eg, smoking history, household size, recent 
antibiotic use) at each swab visit (figure 2). The question-
naire will be re-identified by subject number to link ques-
tionnaire data with carriage data.
Figure 1 Study design.
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Participants will be offered a A$20 iTunes card for 
completion of the questionnaire and oropharyngeal swabs 
to compensate them for their time. An SMS reminder will 
be sent 2 days prior to the school visits to notify parent/
participants of the first and follow-up school visits
All collected data (student consent forms, question-
naires and swab analysis results) will be securely stored 
on a database held by AHTA, The University of Adelaide, 
with access to the database controlled by password protec-
tion. Range and logic checks will be performed on all 
collected data. Any data presented will be de-identified 
prior to presentation.
Patient and public involvement
The research question was developed in response to 
policy advisors’ recommendations. Study materials were 
reviewed by a Youth Advisory Group at several stages 
during study design. Feedback was also sought through 
social media including Twitter, Instagram, Facebook 
and enquires/feedback on the study website, early in 
Figure 2 High school questionnaire.
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development of the website. Student, parent and immu-
nisation ambassadors will support awareness of the study 
and recruitment through schools.
The three Education Sectors (public, independent 
and Catholic schools) in SA will provide informa-
tion to schools and support the study within schools. 
A communications officer will work with stakeholders 
on establishing appropriate and accessible avenues of 
communication. Involving students in the planning 
and delivery of communication strategies is expected to 
facilitate communication and provide opportunities for 
students to engage in research. A multimedia strategy 
will be overseen by the University of Adelaide, with the 
support of a public relations/communications company 
and SA Health. Key activities include website develop-
ment (www. bpartofit. com. au),22 brand identity ‘B Part 
of It’, advertising and creation of supporting materials, 
ambassador engagement, public relations management 
and media training, social media strategy and amplifi-
cation and bespoke content development. Study results 
will be provided to students through communication to 
schools and presentations at public forums. Results will 
also be reported in the media including television, radio 
and print media.
study safety monitoring and surveillance
Vaccine safety will be monitored through the South 
Australian Vaccine Safety Surveillance, an enhanced 
passive surveillance system used for timely detection 
of signals suggestive of an increase in adverse events 
following immunisation. Serious adverse events (SAEs) 
considered possibly or probably related to administra-
tion of 4CMenB vaccine will be reported to the Research 
Ethics Committee, the study sponsor, the Therapeutic 
Goods Administration (Australian Government) and 
the vaccine manufacturer within 72 hours of the site 
becoming aware of the SAE. A study vaccine safety 
committee including independent vaccine safety experts 
has been established and will review all participant-re-
ported safety data in accordance with a vaccine safety 
surveillance protocol.
Monthly summaries of all adverse events reported 
will be provided to the International Scientific Advisory 
Committee (ISAC) and the vaccine manufacturer. The 
ISAC has oversight of the study and has decision-making 
capacity over the scientific, technical and logistical aspects 
of study conduct.
training of immunisation providers
Training for the study has been conducted in metro-
politan Adelaide and major rural locations. A detailed 
training manual and standard medication order has 
been provided to all immunisation providers. Nurses are 
trained in and practice swab collection at the scheduled 
training days to ensure standardised and adequate poste-
rior oropharyngeal swab collection technique. Schools 
will be randomly selected for monitoring of protocol-re-
lated study processes including throat swab technique.
laboratory processes
On receipt of samples, DNA will be extracted using an 
automated extraction on the Roche MagnaPure system 
and subjected to PCR screening for the presence of specific 
meningococcal DNA (using PorA gene detection). Any 
samples yielding a positive PCR will be identified and 
cultured for Neisseria species on selective and non-selec-
tive agar and incubated overnight in CO2 at 35°C. Plates 
will be examined daily for isolates for up to 72 hours. N. 
meningitidis will be identified by standard diagnostic labo-
ratory bacteriological methods using oxidase reaction 
and MALDI ToF with further PCR testing to determine 
the capsular group (A, B, C, W, X, Y).
Quantitative PCR will be applied to the positive screen 
samples for estimation of the density of carriage of the 
Neisseria species.23 A standard curve will be generated 
allowing comparison of crossing point values from the 
specimen analysis with the standard curve allowing the 
estimation of Neisseria density in the specimen. Samples 
will be stored long term in STGG broth at −80°C for 
future whole genome sequencing.24
sample size and analysis plan
Students attending school have been chosen as the 
study population, as carriage of N. meningitidis increases 
from around 15 years of age4 and a funded programme 
for adolescents would likely be introduced in this age 
group. Study results will then predict the likelihood of 
indirect effects of 4CMenB in a national immunisation 
programme, which includes adolescents.
Consistent with previous published carriage rates in 
school students,25 26 we estimate the overall carriage prev-
alence in unvaccinated South Australian adolescents will 
be 6%–8%.
With around 80% uptake and 20% attrition, we antic-
ipate 12 160 vaccinated and 12 160 unvaccinated year 10 
and 11 students with a 12-month oropharyngeal swab. 
Assuming the carriage rate among the unvaccinated 
cohort is 8%, this sample size will provide 90% power to 
detect a 20% relative reduction in carriage to 6.4% in 
vaccinated participants (two tailed alpha=0.05). These 
calculations incorporate a design effect of 2.19, based 
on an average of 120 students per school providing 
12-month swab data and an intraclass correlation coef-
ficient estimate of 0.01 as reported in other studies 
involving students in schools.27 Should uptake or study 
completion be suboptimal, the study will still have 80% 
power provided that at least 8970 participants per arm 
contribute 12-month swab results.
All analyses will be undertaken according to a pre-spec-
ified statistical analysis plan. Available outcome data for 
students will be analysed according to the randomised 
group of their school (intention-to-treat principle). A 
sensitivity per-protocol analysis of the primary outcome 
will also be conducted in vaccine group students who 
followed a two-dose schedule of 4CMenB and control 
group students who did not receive 4CMenB before the 
12-month follow-up.
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The primary outcome of carriage of disease causing N. 
meningitidis genogroups detected by PCR at 12 months 
(yes/no) will be compared between groups using logistic 
regression, with generalised estimating equations (GEEs) 
used to account for clustering at the school level. The 
difference in carriage between groups will be expressed 
as an OR with 95% CI. Adjustment will be made for base-
line carriage, randomisation strata (school size, ICSEA) 
and other baseline variables pre-specified for adjustment. 
Missing data on the primary outcome will be addressed 
using multiple imputation. All secondary outcomes will 
be compared between groups using logistic GEEs. In 
planned subgroup analyses of the primary and secondary 
outcomes, the effect of the 4CMenB vaccine will also be 
examined separately for metropolitan and rural schools 
and year 10 and year 11 students. Effect modification by 
these factors will be assessed separately by including an 
interaction term involving randomised group within each 
statistical model.
dIsCussIon
This study is being conducted in SA which has (1) the 
highest IMD notification rate in Australia with a predom-
inance of serogroup B, and (2) IMD notifications that 
are uniquely higher in adolescents than children. The 
predominant genotype over the past decade in SA is the 
B P1.7–2.4, which is the New Zealand epidemic strain and 
the PorA type contained in 4CMenB. While 4CMenB is 
available and recommended in Australia, uptake on the 
private market has been low and should not impact on 
baseline carriage rates.
It is feasible to conduct a large population study of 
this kind in SA due to the infrastructure and partner-
ships between the University of Adelaide, SA Health, the 
Women’s and Children’s Health Network, the National 
Health and Medical Research Council SA Academic 
Health Science and Translation Research Centre and 
Education sectors (Department of Education, Inde-
pendent and Catholic Schools). The school immunisa-
tion programme that successfully delivers vaccines to 
adolescents supports the feasibility and potential high 
engagement in this study. We are cognisant of the risk of 
potential bias in having a control group with vaccination 
at study completion and potential for disproportionate 
withdrawal from this group; however, we will encourage 
continual involvement in the study and document any 
privately accessed vaccines in these individuals. We are also 
aware of the risk of interoperator variability in oropharyn-
geal swab collection in a study of this size. To mitigate 
this risk, all immunisation providers have been trained 
in a standardised technique for posterior oropharyngeal 
swab collection, which includes face-to-face training and 
unlimited access to a video outlining the swab collection 
technique.
As IMD is rare, the impact of the vaccine on carriage 
is an important component of cost-effectiveness anal-
yses. This study will allow assessment of any association 
between the intervention and changes in carriage prev-
alence, to predict the likelihood of indirect effects of 
4CMenB in reduction in disease in a national immuni-
sation programme, which includes adolescents. A single 
12-month time point for repeat oropharyngeal swabs 
has been chosen for a number of reasons including to 
void any seasonal variation in carriage prevalence and 
to ensure enough time to measure a vaccine effect but 
also to ensure such an effect is sustained in order to be 
confident about a herd immunity impact at a popula-
tion level. This time point is approximately 10 months 
after the second dose of vaccine (12 months post first 
dose), with a previous vaccine effect shown 3 months 
after the second dose in the Read et al study.19 A single 
time point was chosen for feasibility reasons as 6 months 
post dose 2 would occur during the examination period 
and following holidays and there would likely be large 
numbers of students lost to follow-up. The timing of the 
swabs took into account the calendar year and avoided 
the busy periods where there would be competing prior-
ities such as school commencement and other school 
immunisation programmes and enough time for parents 
and students to learn about the study and return consent 
forms and eligibility checklists for careful review by the 
immunisation nurses.
The question of the ability of any vaccine to provide 
indirect effects on the unvaccinated population (ie, 
herd protection) has important implications for vaccine 
policy. This is a particularly important question for 
meningococcal vaccines due to the unique epidemi-
ology of asymptomatic pharyngeal carriage and more 
critically important for protein-based MenB vaccines, 
where limited information exists. High rates of sero-
group B meningococcal disease, despite very low rates of 
carriage in infants, are likely explained by transmission 
from older age groups where carriage rates are relatively 
high. Understanding the potential impact of this vaccine 
on carriage in older age groups has important public 
health implications with the potential to inform world-
wide policy on the implementation of adolescent MenB 
vaccination programmes.
This will be the first study to assess the impact of a 
large population 4CMenB programme on N. meningitidis 
carriage. Understanding any effects on carriage will assist 
Australian regulatory authorities and authorities in other 
countries in assessing the potential indirect effects to 
assist in the cost-effectiveness estimates of a MenB vaccine 
for inclusion in a national immunisation programme. A 
study to examine the impact of 4CMenB and MenB:fHBp 
(Pfizer) on carriage is planned for commencement in 
the UK in 2018 (personal communication Dr Matthew 
Snape, Oxford University). Carriage data will also inform 
the vaccine type and age group for implementation.8 In 
particular, it will be of interest to establish whether the 
remarkable herd protection effect seen with introduction 
of the conjugate meningococcal C vaccines is replicated 
for meningococcal B vaccine, 4CMenB.12 In addition, 
the data gathered in this study will be invaluable for 
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the development of mathematical models to predict 
the outcome of a national 4CMenB immunisation 
programme.
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